Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-743 in Advanced Soft Tissue Sarcomas
NCT00003939Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Primary completion
- Nov 2000
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trabectedin in soft tissue sarcoma (STS), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Therapeutic Activity (Response Rate). Status: completed.
02
Drugs
trabectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00003939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003939.